

<p>Name of Policy: Pregnancy Screening Prior to Nuclear Medicine Therapeutic Procedures</p> <p>Policy Number: 3364-135-163</p> <p>Approving Officer: Assistant Professor & Deputy Clinical Service Chief, Director Radiology</p> <p>Responsible Agent: Assistant Professor & Deputy Clinical Service Chief, Director Radiology</p> <p>Scope: University of Toledo Medical Center Radiology</p>	 <p>Effective date:</p> <p>Original effective date: 11/14/2022</p>
<p>Key words: Therapeutic dose, radioactive materials, pregnancy, AU</p>	
<input type="checkbox"/> New policy proposal <input checked="" type="checkbox"/> Minor/technical revision of existing policy <input type="checkbox"/> Major revision of existing policy <input type="checkbox"/> Reaffirmation of existing policy	

(A) Policy Statement

All female patients of childbearing age (typically 12-60 years old) capable of becoming pregnant, who are undergoing therapeutic administrations of radioactive materials are required to submit to appropriate testing and restrictions to ensure that they are not pregnant at the time of dose administration, and will not become pregnant, until it is determined safe to do so.

Patients who are incapable of becoming pregnant (i.e., documented hysterectomy, menopause, etc.) are exempt from this requirement, policy, and any questions or clarifications regarding exemption must be discussed with the Authorized User (AU) prior to scheduling the procedure.

(B) Purpose of Policy

To prevent a radiopharmaceutical medical event and to eliminate/minimize the possibility of administering a therapeutic dose of radioactive material to an unborn child.

(C) Scope

For applicable patients, the following requirements apply if they are to receive a therapeutic dose of sodium iodine I-131 in activities greater than thirty-three (33) mCi, or for administration of a therapeutic dose of unsealed radioactive material other than I-131:

1. For all female patients:
 1. The intended patient will be required to submit a serum (blood) pregnancy test within twenty-four (24) hours prior to of the intended administration, documenting a negative pregnancy status. Urine or dipstick pregnancy testing is not acceptable.
 2. For all female patients receiving a therapeutic dose of sodium iodine I-131 in activities greater than thirty-three (33) mCi, or for administrations of a therapeutic dose of unsealed radioactive material other than I-131:

Formatted: Font: 10.5 pt

Formatted: Font: 10.5 pt

Formatted: Normal, Indent: Left: 0.35", No bullets or numbering

Formatted: List Paragraph, Numbered + Level: 1 + Numbering Style: 1, 2, 3, ... + Start at: 1 + Alignment: Left + Aligned at: 0.45" + Indent at: 0.7"

Formatted: List Paragraph, Numbered + Level: 1 + Numbering Style: 1, 2, 3, ... + Start at: 1 + Alignment: Left + Aligned at: 0.45" + Indent at: 0.7", Tab stops: Not at 0.38"

Formatted: List Paragraph, Indent: Left: 0.35", No bullets or numbering

2. In addition to part 1, tThe intended patient must also attest and agree to abstention of sexual intercourse for a minimum of ten (10) calendar days prior to the date of administration of the radiopharmaceutical.

3. All patients will also be instructed to utilize effective contraception techniques to ensure that they will not become pregnant or impregnate another individual for at least one (1) year following treatment, or as discussed with the Authorized UserAU.
4. This documentation will be reported and filed with the patient's written radiation safety consultation and instructions and therapy consent paperwork.
5. Verification of pregnancy and breastfeeding status is the responsibility of the Nuclear Medicine Technologist and the Authorized UserAU prior to radiopharmaceutical administration.
6. If it is determined that the patient is pregnant at the time of administration, or that the patient has failed to abstain from sexual intercourse for the timeline stated above ten day period, the exam is to be aborted and/or rescheduled, and testing repeated at an appropriate date.

<p>Approved by:</p> <p>Nathan Egbert, MD Assistant Professor & Deputy Clinical Service Chief</p> <hr/> <p>Date</p> <p>Ryan Landis, BSRT (R)(CT) Director, Radiology</p> <hr/> <p>Date</p> <p>Daniel Barbee Chief Executive Officer UTMC</p> <hr/> <p>Date</p> <p><i>Review/Revision Completed by:</i> Ryan Landis, BSRT (R)(CT)</p>	<p>Policies Superseded by This Policy:</p> <ul style="list-style-type: none"> • <p>Initial effective date: 1/1/2020</p> <p>Review/Revision Date:</p> <p>1/1/2020 1/1/2023 12/1/2025 1/1/2026</p> <p>Next review date:</p>
---	---